Sunshine Biopharma Collaborates For Its Lead MRNA-Based Cancer Program
Sunshine Biopharma Collaborates For Its Lead MRNA-Based Cancer Program
陽光生物製藥公司為其基於Lead mRNA的癌症項目提供合作
- Sunshine Biopharma Inc (NASDAQ:SBFM) has entered into a collaboration agreement with a North American lipid nanoparticle (LNP) company to advance the development of its mRNA-based anticancer macromolecule, K1.1.
- The company's collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma's in-house developed antineoplastic mRNA, K1.1.
- Sunshine Biopharma previously showed that its K1.1 mRNA could destroy cancer cells in vitro, including multidrug-resistant breast, ovarian adenocarcinoma, and pancreatic cancer cells.
- Also Read: EXCLUSIVE: Sunshine Biopharma Acquires Canadian Generic Player For $22M
- Parallel studies using normal human cells showed that K1.1 mRNA had little or no cytotoxic effects.
- The partner-generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers and liver cancer.
- The company can rapidly advance to conducting human trials if these mice studies prove successful. The LNP-formulated K1.1 mRNA can be readily adapted for delivery into patients using the mRNA vaccine technology.
- Price Action: SBFM shares are down 0.23% at $0.84 on the last check Wednesday.
- 陽光生物醫藥公司納斯達克(Sequoia Capital：SBFM)與北美一家脂質納米粒子(LNP)公司達成合作協議，推進其基於信使核糖核酸的抗癌大分子K1.1的開發。
- 該公司的合作伙伴將為陽光生物製藥公司內部開發的抗腫瘤信使核糖核酸K1.1準備兩種LNP配方(K1.1a和K1.1b)。
- 陽光生物製藥公司此前曾表明，其K1.1基因在體外可以殺死癌細胞，包括多藥耐藥乳腺癌細胞、卵巢腺癌和胰腺癌細胞。
- 另請閲讀：獨家報道：陽光生物醫藥以2200萬美元收購加拿大仿製藥公司
- 使用正常人類細胞進行的平行研究表明，K1.1mRNA幾乎沒有或幾乎沒有細胞毒性作用。
- 合作伙伴產生的K1.1a：：LNP和K1.1b：：LNP將用於表達體外測試的人類癌症和肝癌的異種移植小鼠的體內研究。
- 如果這些小鼠研究被證明成功，該公司可以迅速推進到進行人體試驗。使用信使核糖核酸疫苗技術，LNP配製的K1.1信使核糖核酸可以很容易地用於患者體內。
- 價格行動：在週三的最後一次檢查中，SBFM的股價下跌了0.23%，至0.84美元。